Evaluating Biomarkers During Clinical Trials for Immunotherapies: A Case Study on the Pioneer Project, Upcoming Webinar Hosted by Xtalks

Share Article

Identifying immune-related biomarkers is critical for framing combination therapies with checkpoints inhibitors, particularly in a trial setting. Biomarker evaluation allows a comprehensive profiling of the tumor and is mandatory to elucidate actionable or resistance mechanisms to treatment in solid cancers. Learn about these concepts and more by registering for this free webinar.

Xtalks Life Science Webinars

The immune microenvironment is one of the factors that critically influences clinical outcome. Therefore, identifying immune-related biomarkers is of crucial importance in the frame of combination therapies with checkpoint inhibitors.

Immunotherapies are currently the most rapidly growing drug class and have a major impact in the oncology field. While these approaches have demonstrated impressive results for some patients, important challenges still need to be overcome. Among these, defining valuable and adapted combination protocols, predicting responders to therapies through biomarkers, follow-up or overcoming resistance development to current immunotherapies are major goals to achieve.

The immune microenvironment is one of the factors that critically influences clinical outcome. Therefore, identifying immune-related biomarkers is of crucial importance in the frame of combination therapies with checkpoint inhibitors.

On Wednesday, November 27, 2019 at 11am EST (4pm GMT/UK), join a live webinar where Dr Jérôme Galon, Research Director at Inserm, will explain how biomarker evaluation allows a comprehensive profiling of the tumor and is mandatory to elucidate actionable or resistance mechanisms to treatment in solid cancers. Next, Professor Fabrice Barlesi, Head of Multidisciplinary Oncology and Therapeutic Innovations at APHM, will focus on the choice of relevant immune-related biomarkers to be tested in order to predict and overcome resistance to treatments in patients suffering from lung cancer. The Pioneer Project, supported by the French Research Agency, will illustrate this topic.

This webinar will also include a brief overview of a powerful immuno-oncology platform that can provide meaningful and actionable data through biomarker testing.

For more information or to register for this event, visit Evaluating Biomarkers During Clinical Trials for Immunotherapies: A Case Study on the Pioneer Project.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Candice Tang
Xtalks
1 (416) 977-6555
Email >
Visit website